- Strategically
positioned to be a global leader in the CBD space
- Expands
CBD chocolate product line and provides accessibility to consumers in
convenience stores across the U.S.
- Joint
ventures globally in nutraceuticals, pharmaceuticals and medical device
products
Earth Science Tech, Inc. (OTC: ETST) is a Florida-based
biotechnology company focused on cannabis (industrial hemp) and cannabinoid
research and development, nutraceuticals, pharmaceuticals and medical devices.
The company operates through three wholly owned subsidiaries – Earth Science
Pharmaceutical Inc., Cannabis Therapeutics Inc. and KannaBidioiD, Inc. – each
of which are equally invested in developing the company’s role as a global
leader in the CBD space. Last year, the company acquired Canna Inno Laboratories,
Inc. as part of its strategic plan to expand into Canada and gain access to
government grants.
By making its products more available to consumers through
its association with AATAC, an advisory board that focuses on convenience
stores, ETST is setting itself apart as a major provider of premium CBD
products. Through a joint venture with Karmavore Superfoods, the company is
expanding its unique full spectrum cannabinoid CBD raw dark chocolate line from
two to five products. With the anticipated launch of three new CBD-based patent
formulas – chocolate-covered mangoes, chocolate coconut peppermint cups and
chocolate caramelized quinoa crunch – ETST and AATAC anticipate a high volume
of preorders from approximately 90,000 retail outlets throughout the United
States. These chocolates are scheduled to hit the market in the coming weeks.
The move to provide this product in convenience stores provides ETST with the
means to increase its consumer base across every sector of the population. In a
news release (http://ibn.fm/3NhlP),
Jill Buzan, chief sales officer of ETST, stated, “This could lead to huge
exponential growth for ETST’s sales in the next few months.”
The expanded reach throughout the United States is not the
company’s only focus. Its goal is to become a global leader in the CBD space,
and ETST is taking promising steps in that direction.
In March, ETST announced that it had received a grant from
the Government of Quebec to pursue the development of three CBD-based
nutraceutical provisional patent products. These products include a neuron
protector, a breast protector and a product designed to improve antioxidant
ingestion.
Through a joint venture with Bionatus Laboratrio Botnico of
Brazil and its Canadian division, Bionatus Botanical Laboratories, Inc., ETST
has three products in various stages. Propovit’s purpose is to alleviate throat
irritation, colds and bad breath, and it is enriched with ETST hemp oil.
Bionatus is being reformulated with the addition of CBD to potentially enhance
its anti-inflammatory and bronchial-dilation properties. A third product is in
the planning stages, and details will be shared soon.
A pre-launch clinical study of ‘Hygee’ with Clinique Santé
Amitié in Quebec, Canada, is currently being conducted. ‘Hygee’ is the name of
ETST’s MSN-2 home testing medical kit designed for the detection of sexually
transmitted infections (STI), such as chlamydia. This kit will be marketed worldwide,
and the company anticipates approval of the trademark within the next nine to
10 months.
For more information, visit the company’s website at www.EarthScienceTech.com
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
